A phase 3 trial published online on 11 November 2026 found that adding the individualized therapy intismeran autogene to pembrolizumab left more patients recurrence-free at two years than pembrolizumab alone. In The New England Journal of Medicine, as recorded on PubMed, recurrence-free survival at 24 months was 82.2 percent with intismeran plus pembrolizumab and 70.0 percent with placebo plus pembrolizumab. The two-sided P value was under 0.001. Median follow-up was 24.6 months.
The trial, INTerpath-001, enrolled patients with cutaneous melanoma that had been completely removed and was stage IIB to IV. Investigators randomly assigned 1,137 patients, 757 to intismeran and 380 to placebo, in a double-blind ratio of 2 to 1. Everyone received pembrolizumab, 400 milligrams by vein every six weeks for nine cycles. Intismeran, or the matching placebo, was 1 milligram injected into muscle every three weeks for nine doses. The drug is an individualized neoantigen therapy, designed to prompt new T-cell responses against that patient's tumor neoantigens and to widen responses the immune system has already started. The primary result was recurrence-free survival as judged by the investigators. A main secondary result was survival without distant metastasis, also judged by the investigators.
The advantage was not visible in the first six months. For recurrence, the hazard ratio before six months was 0.99, with a 95 percent confidence interval of 0.66 to 1.49, a range that includes no difference. After six months the hazard ratio was 0.42, with an interval of 0.30 to 0.58. Distant-metastasis-free survival at 24 months was 88.5 percent with intismeran and 80.2 percent with placebo (P = 0.002). The same split appeared there: a hazard ratio of 1.01 before six months (interval 0.58 to 1.79) and 0.50 after (interval 0.34 to 0.73).
What the abstract does not show
Grade 3 or higher adverse events occurred in 23.6 percent of the intismeran group and 20.3 percent of the placebo group. Eight patients on the intismeran arm, 1.1 percent, died from an adverse event. Five of those deaths happened before intismeran was given. The abstract does not give a matching death count for the placebo group, and it does not report overall survival, so these figures are not evidence that patients lived longer.
The comparison is with pembrolizumab, which the patients in both groups received, and only after surgery had removed a cutaneous melanoma. The abstract does not report results for people whose melanoma was still in place. Recurrence and metastasis were scored by investigators even though the injections were blinded. Merck Sharp and Dohme and Moderna funded the trial. The author list includes employees of both companies. The paper is a trial report, not an approval, and it does not say the therapy is available as routine care.